cyclophosphamide + etoposide + melphalan

Based on the search results, I'll provide information about the combination drug "cyclophosphamide + etoposide + melphalan" as requested. This combination appears to be used in high-dose chemotherapy regimens, particularly for lymphoma patients. The search results show several studies where these agents are used together, sometimes with additional drugs like busulfan or dexamethasone, as conditioning regimens before autologous stem cell transplantation (ASCT). The combination is used primarily for treating relapsed or refractory lymphomas, including both Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL). According to the search results, this combination has shown efficacy in these conditions, with studies reporting favorable progression-free survival and overall survival rates[1][2]. The toxicity profile includes both hematologic and non-hematologic effects. Common side effects include gastrointestinal toxicity, infections, and potential cardiac toxicity. Melphalan and cyclophosphamide are noted to be arrhythmogenic chemotherapeutic agents[3]. ## Mechanism of Action Each component in this combination has its own mechanism: - **Cyclophosphamide**: An alkylating agent that cross-links DNA, preventing cell division - **Etoposide**: A topoisomerase II inhibitor that causes DNA strand breaks - **Melphalan**: An alkylating agent that forms cross-links between DNA strands Together, these agents provide a multi-targeted approach to killing cancer cells, particularly effective against lymphoma cells. ## Clinical Use This combination is primarily used as a high-dose conditioning regimen before autologous stem cell transplantation in patients with: - Relapsed or refractory Hodgkin lymphoma - Relapsed or refractory non-Hodgkin lymphoma The search results mention several variations of this combination, including: - LEED (melphalan, cyclophosphamide, etoposide, and dexamethasone)[1] - DICEP (dose-intensified cyclophosphamide, etoposide, and cisplatin) followed by high-dose melphalan[2] - BuME (busulfan, melphalan, and etoposide) compared to BuCE (busulfan, cyclophosphamide, and etoposide)[3][5] These regimens have shown promising results in terms of efficacy and safety profiles for lymphoma patients undergoing stem cell transplantation.